Does medical insurance cover important drugs like neratinib/neratinib?

Neratinib/Neratinib is an innovative oral drug. Its mechanism of action is to inhibit the tyrosine kinases of HER1, HER2 and HER4 pan-human epidermal growth factor receptor (HER). In the ExteNET pivotal trial, the drug showed significant efficacy in reducing the risk of recurrence of invasive disease or mortality in women with early-stage HER2-positive breast cancer after completing adjuvant trastuzumab therapy, both 2 and 5 years after randomization.

In China, neratinib has been included in the national Class B medical insurance directory, which is undoubtedly a great benefit for patients who meet specific indications. They can enjoy reimbursement benefits from the national medical insurance, which greatly reduces the financial burden caused by drug costs. However, patients who do not qualify for health insurance will need to pay the full cost of the drug themselves. It should be noted that since the reimbursement ratios of medical insurance vary from place to place, there may be differences in the reimbursement amount enjoyed by patients and the final price paid.

Based on the current domestic market situation, the price of neratinib is relatively high. A box of 40mg*180 tablets costs about 7,000 yuan. However, after reimbursement through medical insurance, the actual cost paid by the patient will be significantly reduced. In addition, generic drugs on overseas markets also provide more choices for patients who need this drug. For example, the price of a generic drug of neratinib produced by Bangladesh Yaopin International is only a fraction of the original drug, about more than 2,000 yuan (the price may fluctuate due to exchange rates), which makes this effective treatment affordable for more patients.